BoomRayBeyond's analysis on BoomRay2026-09-22 — BoomRay secures exclusive global license with Novartis for a novel radioligand therapy, boosting Novartis' oncology pipelineRecent news mentioning BoomRay2026-09-22 — BoomRay Enters Exclusive Global License Agreement with Novartis for a Novel Radioligand Therapy AssetAppears alongsideNovartisBrowse the full archive →